Related Experiment Video

Updated: Jan 14, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.6K

Cystatin C is a potential biomarker for predicting hyperhomocysteinemia associated with chronic kidney disease: A

Bing Luo1, Yun Wang2, Minjie Sun3

  • 1Department of medical laboratory center, Anhui No.2 Provincial People's Hospital, Hefei, Anhui, China.

Science Progress
|October 21, 2025
PubMed

Insights

Cystatin C (CYSC) levels are higher in chronic kidney disease (CKD) patients with hyperhomocysteinemia (HHCY). CYSC may serve as a biomarker for detecting HHCY in CKD patients, aiding cardiovascular risk assessment.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Hyperhomocysteinemia (HHCY) is a significant risk factor for cardiovascular events in chronic kidney disease (CKD) patients.
  • Identifying reliable biomarkers for HHCY in CKD is crucial for risk stratification and management.

Purpose of the Study:

  • To investigate the association between cystatin C (CYSC) and HHCY in individuals with CKD.
  • To determine if CYSC can serve as a biomarker for elevated homocysteine levels in CKD patients.

Main Methods:

  • Retrospective cross-sectional study of 85 CKD patients, divided into normal and high HCY groups.
  • Correlation analysis between CYSC and HCY levels.
  • In vitro experiments involving CYSC overexpression and silencing in mesangial cells.

Main Results:

  • CYSC levels were significantly elevated in CKD patients with HHCY compared to those without.
  • A positive correlation was observed between CYSC and HCY levels (p < 0.05).
  • CYSC was identified as an independent risk factor for HHCY in CKD. In vitro studies confirmed HCY level changes with CYSC manipulation.

Conclusions:

  • CYSC may serve as a potential biomarker for detecting high HCY levels in CKD patients.
  • This finding could improve cardiovascular risk assessment in the CKD population.
  • Further research is warranted to validate CYSC as a clinical biomarker for HHCY in CKD.

Keywords:
Cystatin Cchronic kidney diseasehyperhomocysteinemiainflammatoryoxidative stress

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K
Cytosolic Calcium Measurements in Renal Epithelial Cells by Flow Cytometry10:24

Cytosolic Calcium Measurements in Renal Epithelial Cells by Flow Cytometry

Published on: October 28, 2014

15.7K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
535
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
557
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
335
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
547
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
188
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
361